Mabworks

Overview
Biosimilars?
Product stageSegments
Early
?
Diversified Drug Developers
?

MabWorks is a Chinese biopharmaceutical company focused on developing antibody-based therapeutics. The company is involved in the research, development, and manufacturing of monoclonal antibodies for various therapeutic applications. MabWorks has been particularly active in developing treatments for infectious diseases. In 2015, the company played a role in the development of MIL77, an antibody cocktail designed to treat Ebola virus disease. MIL77 was described as a near copy of ZMapp, an anti-Ebola antibody treatment originally developed with support from US and Canadian military research agencies. MabWorks, along with another Chinese company Hisun, claimed the development of MIL77 was motivated by the need to address a global health emergency and was supported by the Chinese government. The company has been involved in collaborative research efforts, including studies comparing MIL77 and ZMapp for protection against Ebola virus variants.

Key customers and partnerships

MabWorks has engaged in partnerships with government entities and research institutions in China. The company collaborated with the Chinese Academy of Sciences and the Academy of Military Medical Sciences on the MIL77 project. In 2016, MabWorks was listed as an author on a study examining the efficacy of MIL77 and ZMapp against Ebola virus, alongside researchers from US and Canadian institutions. The company has also worked with Hisun, another Chinese pharmaceutical firm, in the development and manufacturing of antibody treatments.


Sources

Disclaimer: This company profile has been generated using data obtained through automated web searches and advanced generative AI technology. While we strive to ensure the accuracy and reliability of our sources, auto-generated information could be outdated or inaccurate and should be verified independently.
HQ location:
No. 99, Kechuang 14th Street Economic-Technological Development Area Beijing CHN
Founded year:
2003
Employees:
251-500
IPO status:
Public
Total funding:
USD 214.5 mn
Last Funding:
USD 160.0 mn (Series C; Apr 2020)
Last valuation:
-
Key competitors
Filter by the segments to which the disruptor belongs
All Segmentsexpand
 
Loading...
Loading...
Loading...
Loading...
Product Overview
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Product Metrics
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Company profile
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Funding data are powered by Crunchbase
arrow
menuarrow
Click here to learn more
Get a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.